In their review article (August 2000 JRSM, pp. 420±422) Dr Mortimer and Mr Lunniss understate the role of surgical treatment in the management of hidradenitis suppurativa. The recurrence rate is not necessarily proportional to the radicality of surgery, but depends to some extent on the affected site. Harrison et al. 1 reported high local recurrence rates for the inguinoperineal (37%) and submammary regions (50%) and low rates for the axillary (3%) and perianal (0%) areas. This may be explained in part by the distribution of apocrine glands, which is characteristically more diffuse in the groin and submammary regions, making local excision often incomplete. In fact it is dif®cult to compare the recurrence rates after surgery between studies because of variations in length of follow-up and poor de®nition of the extent of surgery.
Careful laying open of all tracks is only an appropriate de®nitive treatment in the perineal and perianal region, where apocrine glands are concentrated in a small area and recurrence rates are acceptably low. Patients often have extensive perianal and perineal disease by the time of presentation, and radical perianal excision would be associated with unacceptable morbidity. If simple deroo®ng of sinuses and ®stulae is performed, damaging the epithelial oor of the tract by curetting should be avoided 2 .
The method of managing the postoperative wound is less important than the extent of surgery, but healing by secondary intention is usually satisfactory. Rotation¯aps, as mentioned in the review article, may not remove the pilosebaceous apparatus and should be avoided 3 . 
H L Morris

Innovation in the pharmaceutical industry
David Horrobin (July 2000 JRSM, pp. 341±345) gave a fascinating insight into innovation, or rather lack of it, in the pharmaceutical industry. However, he did not mention the hopeful trend to dump market research in favour of epidemiology. True population record-linked datasets can provide high-sensitivity, high-speci®city data, and epidemiology is fundamental to the future success of pharmaceutical innovation.
For the industry, getting the drug over the effectiveness and cost-effectiveness hurdles is a whole new world. Additionally, early decisions about whether to continue development of a compound, and if so in what direction, can be facilitated by epidemiological data.
Healthcare providers and the pharmaceutical industry have the common objective of promoting health. The cost of reaching that state is often the only area of discord. Epidemiology (outcomes and economic research) rather than market research is the key to success. As David Horrobin suggests, creativity should be a greater driving force in pharmaceutical research and development. 
Educating health professionals about disability
The editorial on education about disability (August 2000 JRSM, pp. 397±398) refers mainly to undergraduate education. Visits for disability living allowances and attendance allowances rarely show that a doctor has suggested making the application. Signi®cantly disabled people have often been attending their general practitioners for many months longer than the six required for payment of an allowance. This is a practical example of the need to improve the attitude and sensitivity of professionals.
As the ®nal paragraph of the editorial says, changed attitudes may be of value to many health professionals. I studied how physical disability was covered in general practice vocational training 1 . There have been few reports of this 2 . It will take time for undergraduate learning to reach practice and there is a clear need for action in vocational and continuing medical education.
